Patents by Inventor James Pannucci
James Pannucci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240075131Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.Type: ApplicationFiled: November 8, 2023Publication date: March 7, 2024Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
-
Publication number: 20230414703Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.Type: ApplicationFiled: June 1, 2023Publication date: December 28, 2023Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
-
Patent number: 11793856Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.Type: GrantFiled: September 9, 2020Date of Patent: October 24, 2023Assignee: Leidos, Inc.Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
-
Patent number: 11578102Abstract: This disclosure provides peptides that bind to LAG3 and can be used to block its interaction with other molecules such as MHC-II, FGL1, and ?-synuclein. These peptides, with their demonstrated activity and short half-life, can be used to activate cellular immunity while significantly reducing the potential for adverse events that is often associated with the antibody-based checkpoint inhibitors. The peptides can be used as stand-alone therapeutics or can be used as immune modulators in combination with other therapies.Type: GrantFiled: July 28, 2021Date of Patent: February 14, 2023Assignee: Leidos, Inc.Inventors: Gabriel M. Gutierrez, James Pannucci, Vinayaka Kotraiah, Timothy W. Phares, Cecilie D. Browne
-
Publication number: 20220395554Abstract: This disclosure provides peptides which bind to LAG3, such as SAPWEPLHWPEDWWQGTGEW (SEQ ID NO:1), and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and ?-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, and enhancing a response to a vaccine.Type: ApplicationFiled: June 30, 2022Publication date: December 15, 2022Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, Timothy W. Phares, James Pannucci, Marc Mansour
-
Patent number: 11407829Abstract: This disclosure provides peptides which bind to LAG3, such as SAPWEPLHWPEDWWQGTGEW (SEQ ID NO:1), and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and ?-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, and enhancing a response to a vaccine.Type: GrantFiled: May 21, 2020Date of Patent: August 9, 2022Assignee: Leidos, Inc.Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, Timothy W. Phares, James Pannucci, Marc Mansour
-
Patent number: 11338040Abstract: This disclosure provides peptide conjugates that are useful for inhibiting the progression of a hyperproliferative disorder, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, enhancing a response to a vaccine, or inhibiting the progression of a synucleinopathy.Type: GrantFiled: June 3, 2021Date of Patent: May 24, 2022Assignee: Leidos, Inc.Inventors: Gabriel M. Gutierrez, James Pannucci, Vinayaka Kotraiah, Timothy W. Phares, Cecille D. Browne
-
Publication number: 20220112243Abstract: This disclosure provides peptides which can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.Type: ApplicationFiled: October 8, 2021Publication date: April 14, 2022Inventors: Gabriel M. Gutierrez, James Pannucci, Michael Ryan Weil, Timothy W. Phares, Vinayaka Kotraiah, Cecille D. Browne, Peter J. Buontempo
-
Publication number: 20220033441Abstract: This disclosure provides peptides that bind to LAG3 and can be used to block its interaction with other molecules such as MHC-II, FGL1, and ?-synuclein. These peptides, with their demonstrated activity and short half-life, can be used to activate cellular immunity while significantly reducing the potential for adverse events that is often associated with the antibody-based checkpoint inhibitors. The peptides can be used as stand-alone therapeutics or can be used as immune modulators in combination with other therapies.Type: ApplicationFiled: July 28, 2021Publication date: February 3, 2022Inventors: Gabriel M. Gutierrez, James Pannucci, Vinayaka Kotraiah, Timothy W. Phares, Cecille D. Browne
-
Publication number: 20210379189Abstract: This disclosure provides peptide conjugates that are useful for inhibiting the progression of a hyperproliferative disorder, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, enhancing a response to a vaccine, or inhibiting the progression of a synucleinopathy.Type: ApplicationFiled: June 3, 2021Publication date: December 9, 2021Inventors: Gabriel M. Gutierrez, James Pannucci, Vinayaka Kotraiah, Timothy W. Phares, Cecille D. Browne
-
Publication number: 20210275669Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.Type: ApplicationFiled: May 12, 2021Publication date: September 9, 2021Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, Timothy W. Phares, James Pannucci
-
Patent number: 11033622Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.Type: GrantFiled: May 25, 2018Date of Patent: June 15, 2021Assignee: Leidos, Inc.Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, Timothy W. Phares, James Pannucci
-
Publication number: 20210000948Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.Type: ApplicationFiled: September 21, 2020Publication date: January 7, 2021Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
-
Publication number: 20200405803Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.Type: ApplicationFiled: September 9, 2020Publication date: December 31, 2020Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
-
Publication number: 20200369766Abstract: This disclosure provides peptides which bind to LAG3 and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and ?-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, and enhancing a response to a vaccine.Type: ApplicationFiled: May 21, 2020Publication date: November 26, 2020Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, Timothy W. Phares, James Pannucci, Marc Mansour
-
Patent number: 10799581Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.Type: GrantFiled: March 1, 2018Date of Patent: October 13, 2020Assignee: Leidos, inc.Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
-
Patent number: 10799555Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.Type: GrantFiled: February 27, 2018Date of Patent: October 13, 2020Assignee: Leidos, Inc.Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
-
Patent number: 10501534Abstract: This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.Type: GrantFiled: September 17, 2018Date of Patent: December 10, 2019Assignees: Leidos, Inc., The U.S. of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Gabriel M. Gutierrez, James Pannucci, Amy Noe, Steve Chienwen Huang, Scott Winram, Annie Xiaoyan Mo
-
Publication number: 20190002545Abstract: This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.Type: ApplicationFiled: September 17, 2018Publication date: January 3, 2019Inventors: Gabriel M. Gutierrez, James Pannucci, Amy Noe, Steve Chienwen Huang, Scott Winram, Annie Xiaoyan Mo
-
Patent number: 10160802Abstract: This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.Type: GrantFiled: February 29, 2016Date of Patent: December 25, 2018Assignees: LEIDOS, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Gabriel M. Gutierrez, James Pannucci, Amy Noe, Steve Chienwen Huang, Scott Winram, Annie Xiaoyan Mo
